This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of crohn's disease: A Synthesis of Findings from 106 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of crohn's disease: A Synthesis of Findings from 106 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Crohn's disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract. There is no cure for Crohn's disease, but there are many effective treatments that can help manage the symptoms and improve quality of life.

Several studies have investigated various treatment options for Crohn's disease. For example, 94 explored the use of adalimumab, a biologic therapy, to maintain remission in Crohn's disease. The study found that adalimumab was effective in maintaining remission, suggesting its potential as a long-term treatment option. Additionally, 22 explored the use of anti-tumor necrosis factor-alpha (TNF-α) antibodies for inducing remission in Crohn's disease, finding that these antibodies could be effective in patients who did not respond well to conventional treatments.

The research also highlights the importance of addressing the underlying causes of Crohn's disease. 55 suggests that abnormal intestinal microbiota might be a contributing factor to persistent inflammation in Crohn's disease. This finding supports the potential role of antibiotics in Crohn's disease therapy, although further research is needed to determine the efficacy of specific antibiotics, such as rifaximin.

Treatment Summary

Treatment options for Crohn's disease vary depending on the severity of the disease, location of the affected area, and patient response to initial treatments. Conventional medications include anti-inflammatory drugs, immunosuppressants, and corticosteroids ( 94 ). For individuals who don't respond to these treatments or lose their effectiveness, biologic therapies like adalimumab ( 94 ) are considered. The study in 77 compared adalimumab to azathioprine, another immunosuppressant, for preventing Crohn's disease recurrence after surgery.

Research is also exploring new treatment options. 67 examined the potential of vercirnon, an oral CCR9 antagonist, as an induction therapy for active Crohn's disease. In addition to medication, nutritional care and lifestyle modifications play a role in managing Crohn's disease. 78 underscores the importance of nutritional support in achieving and maintaining remission.

Benefits and Risks

Benefit Summary

Effective treatment for Crohn's disease can provide the following benefits:

  • Symptom improvement
  • Disease progression control
  • Improved quality of life
  • Prevention of complications

Risk Summary

However, Crohn's disease treatments can also have potential risks:

  • Side effects
  • Increased risk of infections
  • High treatment costs

Comparison Across Studies

Commonalities Across Studies

The studies reviewed highlight a variety of treatment options for Crohn's disease, including medications, nutritional care, and surgical interventions. They also emphasize the need for individualized treatment plans based on each patient's unique needs and response to therapy.

Differences Across Studies

The research reviewed examines different treatment approaches, patient populations, and outcomes. For instance, some studies focused on specific medications like adalimumab, while others explored the role of antibiotics or nutritional therapy. This diversity in research approaches reflects the complexity of Crohn's disease and the ongoing search for effective treatments.

Consistency and Contradictions in Results

While research provides valuable insights into Crohn's disease treatment, there are inconsistencies and contradictions in the results. These discrepancies often stem from variations in study design, patient characteristics, and outcomes assessed. It's important to interpret research findings within their specific context and understand the limitations of each study.

Applying Research Findings to Daily Life

Crohn's disease treatment is a collaborative process between patients and healthcare providers. The best treatment approach is personalized and tailored to individual needs. Regular follow-up with a healthcare provider is crucial for monitoring treatment effectiveness and addressing any potential complications.

Limitations of Current Research

There are limitations to the current research on Crohn's disease treatment. Further studies are needed to:

  • Develop new and more effective treatments
  • Investigate long-term efficacy and safety of current therapies
  • Improve understanding of the underlying mechanisms of Crohn's disease

Future Research Directions

Future research should focus on:

  • Developing novel therapies, including gene therapies and targeted drug delivery systems
  • Understanding the role of gut microbiota in Crohn's disease and developing microbiome-based therapies
  • Improving the quality of life for people with Crohn's disease through personalized management strategies and support groups

Conclusion

Crohn's disease is a complex and challenging condition, but there is hope. Continued research and ongoing collaboration between patients and healthcare providers are essential to developing new treatments, improving existing therapies, and ensuring the best possible care for individuals living with this chronic disease.

Treatment List

  • Adalimumab
  • Azathioprine
  • Anti-inflammatory drugs
  • Immunosuppressants
  • Corticosteroids
  • Biological therapies
  • Anti-TNF-α antibodies
  • Rifaximin
  • Vercirnon
  • Nutritional therapy
  • Surgery
  • Enteral nutrition
  • Budesonide
  • Methotrexate
  • Infliximab
  • Mesalamine
  • Sulfasalazine
  • Ciprofloxacin
  • Probiotics
  • Cannabis

Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 106 papers
Positive Content
94
Neutral Content
5
Negative Content
7
Article Type
41
32
54
39
106

Language : English


Language : English


Language : English


Language : German


Language : English


Language : English


Language : French


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: EshuisEmma J, BemelmanWillem A, van BodegravenAd A, SprangersMirjam A G, BossuytPatrick M M, van Milligen de WitA W Marc, CrollaRogier M P H, CahenDjuna L, OostenbrugLiekele E, SosefMeindert N, VoorburgAnnet M C J, DavidsPaul H P, van der WoudeC Janneke, LangeJohan, MallantRosalie C, BoomMaarten J, LieverseRob J, van der ZaagEdwin S, HoubenMartin H M G, VechtJuda, PierikRobert E G J M, van DitzhuijsenTheo J M, PrinsHubert A, MarsmanWillem A, StockmannHenricus B, BrinkMenno A, ConstenEsther C J, van der WerfSjoerd D J, MarinelliAndreas W K S, JansenJeroen M, GerhardsMichael F, BolwerkClemens J M, StassenLaurents P S, SpanierB W Marcel, BilgenErnst Jan Spillenaar, van BerkelAnne-Marie, CenseHuib A, van HeukelemHenk A, van de LaarArnold, SlotWarner Bruins, EijsboutsQuirijn A, van OoteghemNancy A M, van WagensveldBart, van den BrandeJan M H, van GelovenAnna A W, BruinKarien F, MaringJohn K, OldenburgBas, van HillegersbergRichard, de JongDirk J, BleichrodtRobert, van der PeetDonald L, DekkersPascal E P, GoeiT Hauwy, StokkersPieter C F


Language : English


Language : English


Author: Bar-MeirSimon


Treatment for Crohn's disease typically involves starting with less intensive medications and gradually increasing treatment as the disease worsens (step-up therapy). A newer approach, using biologics and thiopurines as initial treatment (top-down therapy), has been debated, but current recommendations favor the step-up approach. Budesonide is recommended for mild to moderate Crohn's disease, while mesalazine is only slightly better than placebo for small bowel disease. Antibiotics are only recommended for suspected infections. For mild symptoms, no treatment may be an option. Budesonide is preferred to prednisone for mild Crohn's disease as it has fewer side effects. Sulfasalazine and, if needed, steroids can be used for mild colon involvement. Topical treatment may be helpful for disease in the lower part of the colon. Corticosteroids effectively induce remission in Crohn's disease, with success rates of 60-83%. Azathioprine and 6-mercaptopurine are effective for maintaining remission. Methotrexate is another effective option. Once remission is achieved with steroids, long-term treatment with azathioprine is recommended. Mesalazine may reduce the risk of colon cancer, but this is not proven for Crohn's disease. Overall, most people with Crohn's disease have a relatively mild course, making step-up therapy a good approach. While most medications are as effective as infliximab but with fewer side effects, infliximab should be reserved for patients who haven't responded to other treatments.

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: de GroofE Joline, BuskensChristianne J, PonsioenCyriel Y, DijkgraafMarcel G W, D'HaensGeert R A M, SrivastavaNidhi, van AckerGijs J D, JansenJeroen M, GerhardsMichael F, DijkstraGerard, LangeJohan F M, WittemanBen J M, KruytPhilip M, PronkApollo, van TuylSebastiaan A C, BodelierAlexander, CrollaRogier M P H, WestRachel L, VrijlandWietske W, ConstenEsther C J, BrinkMenno A, TuynmanJurriaan B, de BoerNanne K H, BreukinkStephanie O, PierikMarieke J, OldenburgBas, van der MeulenAndrea E, BonsingBert A, SpinelliAntonino, DaneseSilvio, SacchiMatteo, WarusavitarneJanindra, HartAilsa, YassinNuha A, KennellyRory P, CullenGarret J, WinterDesmond C, HawthorneA Barney, TorkingtonJared, BemelmanWillem A


Language : English


Author: KhannaReena, BresslerBrian, LevesqueBarrett G, ZouGuangyong, StittLarry W, GreenbergGordon R, PanaccioneRemo, BittonAlain, ParéPierre, VermeireSéverine, D'HaensGeert, MacIntoshDonald, SandbornWilliam J, DonnerAllan, VandervoortMargaret K, MorrisJoan C, FeaganBrian G,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: PonsioenCyriel Y, de GroofE Joline, EshuisEmma J, GardenbroekTjibbe J, BossuytPatrick M M, HartAilsa, WarusavitarneJanindra, BuskensChristianne J, van BodegravenAd A, BrinkMenno A, ConstenEsther C J, van WagensveldBart A, RijkMarno C M, CrollaRogier M P H, NoomenCasper G, HoudijkAlexander P J, MallantRosalie C, BoomMaarten, MarsmanWillem A, StockmannHein B, MolBregje, de GroofA Jeroen, StokkersPieter C, D'HaensGeert R, BemelmanWillem A,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: MackDavid R, BenchimolEric I, CritchJeff, deBruynJennifer, TseFrances, MoayyediPaul, ChurchPeter, DeslandresColette, El-MataryWael, HuynhHien, JantchouPrévost, LawrenceSally, OtleyAnthony, SherlockMary, WaltersThomas, KappelmanMichael D, SadowskiDan, MarshallJohn K, GriffithsAnne


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : German


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.